openPR Logo
Press release

Recent Research on Biosimilar Monoclonal Antibodies Market by 2023 Future Insights, Share, Demand, Sales, Key Companies and Trends Analysis

01-31-2018 01:25 PM CET | Health & Medicine

Press release from: Infinium Global Research

Recent Research on Biosimilar Monoclonal Antibodies Market

The global biosimlar monoclonal antibodies market is projected to grow at a CAGR of 42.8% over the period of 2017 to 2023 and reach to USD 8.97 billion by the end of 2023, states Infinium Global Research in its new report on global biosimilar monoclonal antibodies market. The report also identifies that with an expiry of several blockbuster drugs several biosimilar drugs to experience significant opportunities over the next few years. According to the report Patent expiration of biologics, innovative product in the pipeline and increasing healthcare infrastructure are expected to be key factors driving the growth of global biosimilar monoclonal antibodies market. Moreover, rising demand for biosimilar drugs owing to their cost effectiveness, is expected to inflate the market size of biosimilar drugs over the forecast period. However, unfavorable government regulations and development policies, undesirable manufacturing process and cost structure associated with the manufacturing process are considered to be restraining factors in the global biosimilar monoclonal antibodies market.

Get Sample Copy of this Report: https://www.infiniumglobalresearch.com/Reports/MakeSampleRequest/72

Globally, the rising geriatric population in countries such as Germany, the U.S., Japan and the United Kingdom is likely to experience growing prevalence of prevalence diseases such as cancer and diabetes. Oncology and autoimmune diseases are likely to be more prevalent in the geriatric population.  Therapeutics for such chronic diseases are costly and are likely to provide opportunities for low cost biosimilar drugs over the forecast period.

The report segments the global biosimilar monoclonal antibodies market by drug class and by application.The market segmentation based on drug class includes, rituximab, infliximab, abciximab, trastuzumab, adalimumab, and bevacizumab. Moreover, based on application the biosimilar monoclonal antibodies market is segmented into oncology, chronic and auto immune diseases, growth hormone deficiency and infectious diseases.

Some of the key players in the global Biosimilar Monoclonal Antibodies market are PFIZER, INC., Novartis AG, Reliance Life Sciences, Allergan plc, CoherusBioSciences, Inc., Biocon, Dr. Reddy’s Laboratories Ltd, BoehringerIngelheim GmbH., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, BIOCAD, GenorBioPharma Co. Ltd., and Celltrion, Inc.

Make an Enquiry: https://www.infiniumglobalresearch.com/Reports/MakeEnquiryRequest/72

The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand globally as well as regionally. Moreover, Infinium Global Research- Growth Matrix (IGR- Growth Matrix) given in the report brings an insight on the investment areas that existing or new market players can consider.

The report provides insights into the market using analytical tools such as Porter’s five forces analysis and value chain analysis of Biosimilar Monoclonal Antibodies Market. Moreover, the study highlights current market trends and provides forecast from 2017 to 2023. We also have highlighted future trends in the Biosimilar Monoclonal Antibodies Market that will impact the demand during the forecast period.The report presents analysis of global as well as regional markets of Biosimilar Monoclonal Antibodies Market over the period of 2017 to 2023.The competitive analysis given in each regional market brings an insight on the market share of the leading players.

Buy This Report: https://www.infiniumglobalresearch.com/Reports/BuyNowReport/72

Reasons to buy this report

Comprehensive analysis of global as well as regional markets of Biosimilar Monoclonal Antibodies Market.
Complete coverage of all the type, form, processing, and application segments to analyze the trends, developments, and forecast of market size up to 2023.
Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
Infinium Global Research- Growth Matrix presents analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

About Us

Infinium Global Research and Consulting Solutions is started with a single motto of being business partner of first choice. We at Infinium work on the strengths of our clients to ensure we help them consolidate their market position. We firmly believe in the fact that ‘if you are able to develop newer opportunities then you find there is no dearth of opportunities for you. With our strategic research approaches and deep dive in the market segments, we try to find out new opportunities that our clients can encash with their existing resources. Our experts with over 100 years of cumulative experience in research offer the best in the industry services to our clients to ensure that they achieve their business goals.

Contact Us

Infinium Global Research,
Toll Free:
U.S. + Canada: 1-800-638-0796,
UK: +44-2033182010
Website : https://www.infiniumglobalresearch.com
Email: sales@infiniumglobalresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Recent Research on Biosimilar Monoclonal Antibodies Market by 2023 Future Insights, Share, Demand, Sales, Key Companies and Trends Analysis here

News-ID: 924781 • Views:

More Releases from Infinium Global Research

Global Aircraft Tyre Market Size Worth USD 2478.09 Million By 2030 | CAGR 5.47%: Infinium Global Research
Global Aircraft Tyre Market Size Worth USD 2478.09 Million By 2030 | CAGR 5.47%: …
Infinium Global Research, a prominent market research firm, has released an in-depth report providing a comprehensive analysis of the Global Aircraft Tyre Market. The report dives into segments and sub-segments, highlighting both global trends and regional insights that significantly impact this dynamic industry. To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/market-reports/sample-request/1058 Steady Market Growth The global aircraft tyre market, valued at USD 1634.41 million in 2022, is anticipated to surge to
Global Automotive Interior Leather Market to Hit USD 61.6 Billion, Globally By 2030 at 6.50% CAGR | Infinium Global Research
Global Automotive Interior Leather Market to Hit USD 61.6 Billion, Globally By 2 …
Infinium Global Research, a leading research firm, has published an extensive report providing a detailed analysis of the Global Automotive Interior Leather Market. The report offers comprehensive insights into segments and sub-segments, highlighting both global trends and regional dynamics shaping this thriving industry. To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/market-reports/sample-request/1266 Steady Market Growth The global automotive interior leather market, valued at USD 30.82 billion in 2022, is projected to skyrocket
Global Automatic Car Wash Market Growing at a CAGR of 4.01% to Reach USD 5.82 Billion By 2030 | Infinium Global Research
Global Automatic Car Wash Market Growing at a CAGR of 4.01% to Reach USD 5.82 Bi …
Infinium Global Research, a leading authority in market analysis, has released an extensive report offering a deep dive into the Global Automatic Car Wash Market. The report presents an in-depth analysis of segments and sub-segments, shedding light on both global trends and regional dynamics impacting this burgeoning industry. To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/market-reports/sample-request/1295 Robust Market Growth The automatic car wash market, valued at USD 4.04 billion
Global Automotive Logistics Market is Anticipated to Reach USD 363.03 Billion at a Robust CAGR of 5.51% Between 2023 to 2030 | Infinium Global Research
Global Automotive Logistics Market is Anticipated to Reach USD 363.03 Billion at …
Infinium Global Research, a leading market research firm, has released an expansive report offering an in-depth analysis of the Global Automotive Logistics Market. The report delves into crucial segments and sub-segments, shedding light on both global and regional dynamics impacting this intricate industry. The comprehensive study reveals the profound impact of drivers, restraints, and macro indicators on the automotive logistics market. Providing a comprehensive outlook, the report highlights evolving trends, forecasts,

All 5 Releases


More Releases for Biosimilar

Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.